argenx SE (ARGX)

375.00 -0.08 (-0.02%) At close: 04:00PM EDT

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,148

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.	CEO & Executive Director	1.29M	N/A	1972
Mr. Karl Gubitz	Chief Financial Officer	843.26k	N/A	1970
Ms. Karen Massey	Chief Operating Officer	1.42M	N/A	1979
Mr. Filip Borgions	VP & Global Head of Technical Operations	N/A	N/A	N/A
Mr. Peter Ulrichts	Chief Scientific Officer	N/A	N/A	1980
Ms. Beth DelGiacco	VP and Global Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Malini Moorthy	General Counsel	N/A	N/A	1970
Mr. Arjen Lemmen M.Sc.	Vice President of Corporate Development & Strategy	N/A	N/A	1985
Mr. Marc Schorpion	Global Head of Human Resources	N/A	N/A	1959
Ms. Andria Wilk	Global Head of Quality	N/A	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Corporate governance

argenx SE’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.